share_log

东瑞制药(02348.HK)年度母公司拥有人应占溢利约3.26亿元 同比下降约9.0%

The annual profit attributable to owners of Dongrui Pharmaceuticals (02348.HK) was about 326 million yuan, a year-on-year decrease of about 9.0%

Gelonghui Finance ·  Mar 22 11:03

Gelonghui, March 22丨Dongrui Pharmaceutical (02348.HK) announced that for the year ended December 31, 2023, the company recorded revenue of about RMB 1.15 billion, a year-on-year decrease of about 9.9%. Profit attributable to owners of parent companies was approximately RMB 326 million, a year-on-year decrease of approximately 9.0%. The Board recommended a year-end dividend of HK$0.065 per share.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment